drugset / Trial / NCT00620308

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308 ↗

Phase 1 Completed 19 enrolled Mayo Clinic
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This human physiologic study will evaluate the effects of a new drug called CD-NP in individuals with stable chronic heart failure, with a focus on evaluating responses of the kidneys and the hormonal system.

Timeline

Start
2008-06
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenderitide Peptide 20 ng Intravenous